Showing posts with label 2017 TAG Pipeline Report. Show all posts
Showing posts with label 2017 TAG Pipeline Report. Show all posts

Thursday, July 20, 2017

TAG HCV Pipeline Report: DAAs and Diagnostics in the Pangenotypic Era

In Case You Missed It - TAG Pipeline Report HIV, TB, and HCV

Treatment Action Group (TAG) is an independent, activist and community-based research and policy think tank fighting for better treatment, prevention, a vaccine, and a cure for HIV, tuberculosis, and hepatitis C virus.

Follow On Twitter

The 2017 Pipeline Report
July 2017

HIV, TB, and HCV
Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development
Written by Mike Frick, Annette Gaudino, Mark Harrington, Tim Horn, Richard Jefferys, Jeremiah Johnson, Erica Lessem, Marcus Low, and Lindsay McKenna

Hepatitis C
Annette Gaudino
AbbVie, Gilead, Merck, and Janssen have presented data at international congresses on efficacy across the six major genotypes; in difficult-to-treat populations, including patients with genotype 3 and cirrhosis; and patients with advanced kidney disease. Gilead also recently received approval for previously untreated adolescents, and presented data on ongoing clinical trials in young children. It would not be hyperbole to state that science has solved chronic HCV infection for all but individuals with decompensated cirrhosis—yet another powerful argument for early treatment. It must be noted that, as historically has been the case, all clinical trial data is based on majority male patient populations, with few people of color, particularly African Americans, taking part in clinical trials....

Updates On This Blog
Gilead's VoseviTM (Sofosbuvir/Velpatasvir/Voxilaprevir FDA Approved
On July 18, 2017 Gilead's VoseviTM (Sofosbuvir/Velpatasvir/Voxilaprevir) was FDA approved,
last month CHMP - the scientific committee of the European Medicines Agency adopted a positive opinion on the company’s marketing authorization application for Vosevi.

In this year's report: